Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Citigroup from $60.00 to $62.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price target would indicate a potential upside of 324.66% from the company’s previous close.

Several other analysts also recently issued reports on OLMA. Stifel Nicolaus started coverage on Olema Pharmaceuticals in a research note on Wednesday, February 11th. They issued a “buy” rating and a $48.00 price target for the company. HC Wainwright lowered their price objective on Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. The Goldman Sachs Group lifted their target price on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. boosted their target price on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.89.

Olema Pharmaceuticals Trading Down 3.1%

Shares of OLMA stock opened at $14.60 on Tuesday. Olema Pharmaceuticals has a 12-month low of $2.86 and a 12-month high of $36.26. The company has a market capitalization of $1.00 billion, a PE ratio of -7.85 and a beta of 1.92. The firm has a 50 day moving average price of $23.56 and a two-hundred day moving average price of $18.70. The company has a quick ratio of 8.03, a current ratio of 9.95 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01. As a group, analysts predict that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.

Insider Activity

In related news, insider David C. Myles sold 50,000 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $27.60, for a total value of $1,380,000.00. Following the transaction, the insider owned 542,761 shares in the company, valued at approximately $14,980,203.60. This trade represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Naseem Zojwalla sold 99,509 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the completion of the transaction, the insider owned 4,488 shares of the company’s stock, valued at $124,138.08. The trade was a 95.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 805,501 shares of company stock worth $23,003,832. 16.36% of the stock is owned by insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Large investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of Olema Pharmaceuticals during the 4th quarter worth $1,061,000. Invesco Ltd. boosted its stake in shares of Olema Pharmaceuticals by 25.0% in the 4th quarter. Invesco Ltd. now owns 155,732 shares of the company’s stock valued at $3,893,000 after purchasing an additional 31,098 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at approximately $250,000. Vestal Point Capital LP acquired a new position in Olema Pharmaceuticals during the 4th quarter worth approximately $41,250,000. Finally, Wellington Management Group LLP lifted its stake in Olema Pharmaceuticals by 8.2% in the 4th quarter. Wellington Management Group LLP now owns 220,971 shares of the company’s stock valued at $5,524,000 after purchasing an additional 16,764 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Trending Headlines about Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Major price‑target upgrades from big banks: Citigroup raised its target to $62 (buy) and JPMorgan bumped its target to $58 (overweight), signaling outsized upside relative to the current share level and supporting buy‑side interest. Benzinga
• Positive Sentiment: HC Wainwright lifted earnings estimates across multiple quarters and extended horizon upgrades (FY2026–FY2030) while keeping a Buy rating and $38 target — this reduces near‑term downside in forecasts and is a supportive fundamental datapoint. MarketBeat
• Positive Sentiment: Recent operational/clinical and earnings headlines have attracted capital: a report notes a $68.7M investor bet tied to a breast cancer drug aimed at a 2027 launch, and coverage noting the stock rallied after better‑than‑expected earnings — both draw attention from momentum and event‑driven investors. Globe and Mail American Banking News
• Neutral Sentiment: Presentation of preclinical data at AACR (palazestrant & OP‑3136) is a nearer‑term scientific catalyst; positive data would be bullish, but upcoming abstracts/presentations are binary and uncertain. Business Insider
• Neutral Sentiment: Technicals show a steep recent pullback (down ~33% in 4 weeks) and the stock is in oversold territory—this could set up a short‑term reversal if selling eases, but it also reflects volatility after the prior run. Zacks
• Neutral Sentiment: Guggenheim trimmed its target slightly (to $38) but maintained a Buy — a modest downgrade of enthusiasm rather than a reversal. Benzinga
• Negative Sentiment: Goldman Sachs cut its target from $38 to $27 (still a Buy), which reduces consensus upside and may weigh on sentiment for more cautious investors; mixed analyst signals increase short‑term volatility. Benzinga

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.